Curis sell-off overdone, says RBC Capital

RBC Capital reports that Curis' CUDC-907 drug, a blood cancer treatment, was active and tolerable in a recent study. The firm expects questions about the drug to be resolved next year and it keeps an Outperform rating on the shares.


View Comments (0)

Recommended for You